← All trials
NCT04556526
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 5, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Feb 1, 2023
- First posted
- Sep 21, 2020
- Last posted
- Dec 23, 2020
- Enrollment
- 2500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVStudy director
- Emory UniversityCollaborator
- Coalition for Epidemic Preparedness InnovationsCollaborator
- Coalition for Epidemic Preparedness InnovationsCollaborator
- Center for Family Health Research (CFHR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.